A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Venetoclax
DRUG: Acalabrutinib
DRUG: Obinutuzumab

Sponsor

AbbVie